Payment overview · 2025
General Payments
$1,795.82
42 reported records · 10 companies
Healthcare provider profile · identity verified
Hasan M. Mousli, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LAKE WALES, FL · NPI 1710984679
Verified facts
What the public records show
CMS Open Payments records show Hasan M. Mousli, MD received $1,795.82 in general payments during 2025 across 42 reported records.
SI-BONE, INC. accounted for 57.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ubrelvy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $1,038.75 | 57.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $339.88 | 18.9% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $208.53 | 11.6% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$67.39 | 3.8% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $33.73 | 1.9% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $30.29 | 1.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.56 | 1.4% | 1 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $18.36 | 1.0% | 1 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $16.96 | 0.9% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.37 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $912.38 | 38 |
| Travel and Lodging | $883.44 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IFUSE IMPLANT SYSTEM Normalized: ifuse implant system |
Device | SI-BONE, INC. | $903.44 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $254.99 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $254.99 | 15 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $208.53 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $96.02 | 5 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $84.89 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $67.39 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 1655 | 189 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 1298 | 271 |
| Ibuprofen | Ibuprofen | 1017 | 232 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 984 | 148 |
| Gabapentin | Gabapentin | 812 | 163 |
| Tizanidine Hcl | Tizanidine Hcl | 642 | 118 |
| Diclofenac Sodium | Diclofenac Sodium | 606 | 175 |
| Tramadol Hcl | Tramadol Hcl | 568 | 145 |
| Pregabalin | Pregabalin | 349 | 66 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 331 | 89 |
| Donepezil Hcl | Donepezil Hcl | 316 | 96 |
| Levetiracetam | Levetiracetam | 265 | 47 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 240 | 54 |
| Alprazolam | Alprazolam | 213 | 79 |
| Topiramate | Topiramate | 185 | 40 |
| Baclofen | Baclofen | 157 | 35 |
| Trazodone Hcl | Trazodone Hcl | 156 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 154 | 32 |
| Primidone | Primidone | 147 | 39 |
| Methylprednisolone | Methylprednisolone | 123 | 84 |
| Sumatriptan Succinate | Sumatriptan Succinate | 116 | 26 |
| Carisoprodol | Carisoprodol | 113 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 24 |
| Lamotrigine | Lamotrigine | 103 | 21 |
| Memantine Hcl | Memantine Hcl | 93 | 34 |
| Naproxen | Naproxen | 93 | 27 |
| Meloxicam | Meloxicam | 89 | 22 |
| Propranolol Hcl | Propranolol Hcl | 82 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 66 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 15 |
| Celecoxib | Celecoxib | 61 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Entacapone | Entacapone | 60 | 13 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Methadone Hcl | Methadone Hcl | 56 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 52 | 14 |
| Ubrelvy | Ubrogepant | 52 | 13 |
| Oxcarbazepine | Oxcarbazepine | 51 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 45 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 44 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Prednisone | Prednisone | 31 | suppressed |
| Teriflunomide | Teriflunomide | 30 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 28 | 25 |
| Lacosamide | Lacosamide | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 21 | suppressed |
| Botox | Onabotulinumtoxina | 20 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Lyrica | Pregabalin | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Qulipta | Atogepant | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Triazolam | Triazolam | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,795.82 · 42 records | SI-BONE, INC. | AMPYRA, Briviact, CREXONT, IFUSE IMPLANT SYSTEM, INBRIJA, Leqembi, NURTEC ODT, Ocrevus Zunovo, PRECIVITYAD2, QULIPTA, UBRELVY, VALTOCO, VYALEV, Xeomin, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error